Overview
NICE is unable to make a recommendation on cemiplimab (Libtayo) for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer in adults. This is because Sanofi did not provide an evidence submission.
Last reviewed: 1 December 2022
Next review: We will review this decision if the company decides to make a submission.